Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€53.50

€53.50

-4.460%
-2.5
-4.460%
€71.73
 
23.12.25 / Tradegate WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Cytokinetics Inc. Stock

Cytokinetics Inc. took a tumble today and lost -€2.500 (-4.460%).
The stock is an absolute favorite of our community with 38 Buy predictions and no Sell predictions.
As a result the target price of 71 € shows a positive potential of 32.71% compared to the current price of 53.5 € for Cytokinetics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Cytokinetics Inc. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Cytokinetics Inc. in the next few years

Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Comments

Cytokinetics (NASDAQ:CYTK) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for CYTK provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -3.60%
Target price 116.062
Change
Ends at 22.12.26

Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at HC Wainwright from $120.00 to $136.00. They now have a "buy" rating on the stock.
Ratings data for CYTK provided by MarketBeat
Show more

Cytokinetics (NASDAQ:CYTK) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Ratings data for CYTK provided by MarketBeat
Show more

News

This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/1a599f395be31e2f508c3aa7decb988f9ce983b7-1401x1251.png?w=1401&h=1251
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?

B. Lynne Parshall, Director at Cytokinetics, Incorporated (NASDAQ:CYTK), reported the sale of 5,000 shares in an open-market transaction valued at ~$323,650 on November 19, 2025; direct ownership

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares: https://cdn.content.foolcdn.com/images/1umn9qeh/production/280eca1b4ecd8cc2401a2f4b2c3a68395e00dc85-1401x1251.png?w=1401&h=1251
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares

Foresite Capital Management IV, LLC disclosed a new stake in Cytokinetics (NASDAQ:CYTK), adding 458,295 shares valued at $25.19 million as of Sept. 30, 2025. The move was detailed in a quarterly

CYTK Earnings Jump 3,065%
CYTK Earnings Jump 3,065%

Cytokinetics (NASDAQ:CYTK), a late-stage biopharmaceutical company focused on cardiovascular disease, reported earnings for Q2 FY2025 on August 7, 2025. The headline news was a dramatic